老年急性ST段抬高型心肌梗死患者介入治疗后可溶性CD146水平的预后价值  

Prognostic value of soluble CD146 in elderly patients with acute ST segment elevation myocardial infarction after PCI

作　　者：陆荣荣 薄利雪 吾麦尔江·克力木 Lu Rongrong;Bo Lixue;Wumaierjiang·Kelimu(Department of Cardiology,Second People's Hospital of Kashgar Prefecture,Kashgar 844000,Xinjiang Uygur Autonomous Region,China)

机构地区：[1]新疆喀什地区第二人民医院心内科,844000 [2]新疆喀什地区第二人民医院门诊部,844000

出　　处：《中华老年心脑血管病杂志》2024年第2期147-150,共4页Chinese Journal of Geriatric Heart,Brain and Vessel Diseases

基　　金：新疆维吾尔自治区天山英才计划(2021046)。

摘　　要：目的探讨老年急性ST段抬高型心肌梗死(STEMI)患者经皮冠状动脉介入治疗(PCI)后外周血可溶性CD146(sCD146)作为远期生存获益标志物的价值。方法选取2021年1月至2022年7月于新疆喀什地区第二人民医院明确诊断为急性STEMI并行PCI的患者210例,根据PCI后外周血sCD146水平将患者分为低水平组69例,中水平组65例,高水平组76例。进行随访,终点事件包括全因死亡、心脏死亡和主要不良心血管事件(MACE)。采用Kaplan-Meier曲线比较各组累积生存率,采用Cox回归分析外周血sCD146水平与患者预后的关系。结果高水平组发生死亡和MACE比例显著高于低水平组和中水平组(P<0.05)。Kaplan-Meier曲线分析显示,高水平组累积生存率显著低于低水平组和中水平组(P<0.05)。Cox回归分析显示,PCI后外周血sCD146水平与患者PCI后发生死亡独立相关(OR=1.530,95%CI:1.144~2.044,P=0.004)。结论急性STEMI患者PCI后外周血sCD146水平与远期生存获益密切关联,sCD146可作为评估患者远期生存获益的生物标志物。Objective To explore the value of peripheral blood sCD146 as a long-term survival benefit marker in elderly patients with acute ST segment elevation myocardial infarction(ASTEMI)after PCI.Methods A total of 210 patients who were diagnosed with ASTEMI and underwent PCI in our hospital from January 2021 to July 2022 were enrolled,and according to the postoperative sCD146 level,they were divided into low-,medium-and high-level groups(69,65 and 76 cases respectively).All of them were followed up,with endpoint events including all cause death,cardiac death,and major adverse cardiovascular events(MACE).Kaplan-Meier survival curve was plotted to compare the cumulative survival rate of each group,and COX regression analysis was used to analyze the relationship between peripheral blood sCD146 level and prognosis.Results The mortality rate and MACE incidence were significantly higher in the high-level group than the low-and medium-level groups(P<0.05).Kaplan-Meier curve analysis showed that the high-level group had obviously lower cumulative survival rate than the other two groups(P<0.05).COX regression analysis revealed that the sCD146 level in peripheral blood after PCI was independently correlated with the occurrence of death in ASTEMI patients after PCI(OR=1.530,95%CI:1.144-2.044,P=0.004).Conclusion The peripheral blood level of sCD146 is closely related to long-term survival benefits in ASTEMI patients after PCI,and sCD146 can be used as a biomarker to evaluate their long-term survival benefits.

关 键 词：心肌梗死 经皮冠状动脉介入治疗 预后 CD146抗原 

分 类 号：R542.22[医药卫生—心血管疾病]